MedTrace Logo

An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis

NCT03758716 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-04-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis

Conditions

Interventions

DRUG

FB825, FB825-15D11, Anti-CemX

Pharmaceutical form: 20mg/ml solution Route of administration: IV

Sponsors & Collaborators

  • Fountain Biopharma Inc.

    lead INDUSTRY

Principal Investigators

  • Chia-Yu Chu, MD-PhD · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-03
Primary Completion
2019-01-28
Completion
2019-09-19

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03758716 on ClinicalTrials.gov